Internal Medicine Alert
RSSArticles
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
-
Momelotinib Tablets (Ojjaara)
Momelotinib can be prescribed to treat intermediate- or high-risk myelofibrosis.
-
Aberrant Conduction?
How should one interpret the ECG in the figure? Is the rhythm most likely to be a re-entry supraventricular tachycardia with aberrant conduction?
-
Turmeric (Curcumin) Helps Patients with Dyspepsia and Acid Reflux
In a randomized, controlled trial, curcumin demonstrated comparable efficacy to omeprazole in treating dyspepsia and acid reflux.
-
Treating Preclinical Alzheimer’s Disease
After studying an anti-amyloid antibody, solanezumab, researchers reported there was no benefit in reducing the likelihood of progression of cognitive impairment in patients with positive amyloid PET scans who started the trial cognitively unimpaired, compared to placebo.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
An analysis of the Harmony Outcomes study and a meta-analysis combining it with the AMPLITUDE-O study of the addition of a glucagon-like peptide 1 receptor agonist (GLP-1 RA) in a subgroup of type 2 diabetes patients on baseline sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy has shown that major adverse cardiovascular events are reduced by GLP-1 RA, regardless of baseline SGLT2 use, and there was no difference in serious adverse events.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
-
Canakinumab Injection (Ilaris)
Canakinumab can be prescribed to adults with gout in whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
-
More Reports of Severe Group A Streptococcal Infection
Around the world, rates of severe illness caused by group A Streptococcus are rising. Possible explanations for the increase include immunity-altering, post-pandemic changes in exposure to respiratory pathogens and the emergence of new pathogenic M strains of Streptococcus.